{"id":"pegylated-rhg-csf-100-g-kg","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Splenomegaly"},{"rate":"5-10","effect":"Elevated uric acid"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils. Pegylation extends the drug's half-life by reducing renal clearance and increasing circulation time, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of neutrophil counts, reducing infection risk in patients with chemotherapy-induced neutropenia or other neutropenic conditions.","oneSentence":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:08.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN)"},{"name":"Severe congenital neutropenia"},{"name":"Idiopathic or cyclic neutropenia"}]},"trialDetails":[{"nctId":"NCT04497701","phase":"NA","title":"Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Lymphoma, Leukemia","enrollment":139},{"nctId":"NCT02119715","phase":"PHASE2","title":"A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2011-02","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":182},{"nctId":"NCT01611051","phase":"PHASE3","title":"A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-03","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":330},{"nctId":"NCT01560195","phase":"PHASE3","title":"A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-04","conditions":"NSCLC, Neutropenia, Febrile Neutropenia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pegylated rhG-CSF: 100µg/kg","genericName":"Pegylated rhG-CSF: 100µg/kg","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}